Stockscreener 앱 받기
15.31
8.05%
-1.3409
전일 마감가:
$16.65
열려 있는:
$16.91
하루 거래량:
4,658
Relative Volume:
1.00
시가총액:
$20.90M
수익:
$226.00K
순이익/손실:
$-20.18M
주가수익비율:
-15.78
EPS:
-0.97
순현금흐름:
$-17.40M
1주 성능:
-13.14%
1개월 성능:
-40.58%
6개월 성능:
+1,438%
1년 성능:
+1,438%
1일 변동 폭
$14.14
$16.91
1주일 범위
$14.14
$20.60
52주 변동 폭
$14.14
$43.14
온코노바 세러퓨틱스 Stock (ONTX) Company Profile
명칭
Onconova Therapeutics Inc
전화
267 759 3680
주소
12 Penns Trail, Newtown, PA
Compare ONTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONTX
Onconova Therapeutics Inc
|
15.31 | 20.90M | 226.00K | -20.18M | -17.40M | -0.97 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
온코노바 세러퓨틱스 Stock (ONTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | H.C. Wainwright | Buy |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-18 | 개시 | Guggenheim | Buy |
| 2018-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-09 | 개시 | H.C. Wainwright | Buy |
| 2017-04-27 | 개시 | Laidlaw | Buy |
| 2015-07-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 개시 | H.C. Wainwright | Buy |
모두보기
온코노바 세러퓨틱스 주식(ONTX)의 최신 뉴스
TRAWTraws Pharma Inc Stock Price and Quote - Finviz
Pharmazz, Inc. Appoints Ajay Bansal as Chief Financial Officer - Yahoo Finance
Q4 2025 Traws Pharma Inc Earnings Call Transcript - GuruFocus
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - PR Newswire
Oncology Clinical Trials Market Size, Share, Growth, Analysis, 2034 - Straits Research
PI3K Inhibitors Clinical Trials Analysis 2025: Pipeline Analysis, Competitive Landscape, Emerging Therapies, Companies, and Future Outlook by DelveInsight - The Globe and Mail
Annovis Appoints Mark Guerin as Chief Financial Officer - citybiz
Rigosertib Shows Promise in EB-Associated Skin Cancer - Medscape
ONTX Stock Price, News & Analysis - Stock Titan
Huadong Medicine and Synerk to jointly develop siRNA drug - BioWorld MedTech
Onconova Therapeutics (NASDAQ: ONTXW)Share Price - intelligentinvestor.com.au
‘Best-In-Class Virology And Oncology’: Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Combine to Form Traws Pharma, Inc. - orrick.com
Traws Pharma (TRAW) Stock Price, News & Analysis - MarketBeat
10 High-Volume Penny Stocks and Trading Strategies - StocksToTrade
Onconova and Trawsfynydd merge to form Traws Pharma By Investing.com - Investing.com UK
PI3K Inhibitors Clinical Trial Pipeline Experiences - GlobeNewswire
We Think Onconova Therapeutics (NASDAQ:ONTX) Needs To Drive Business Growth Carefully - Yahoo Finance
Zim Doctor Appointed Chief Medical Officer in UK - ZimEye
Penny Stocks To Buy Now? 5 With Big News Today - PennyStocks.com
Onconova Therapeutics Touts Additional Positive Data For Rigosertib Monotherapy In Skin Cancer Setting - Yahoo Finance
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors - citybiz
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022 - The Globe and Mail
Corgi Onto 2X Daily ETF (ONTX-A) Stock Price and News - The Globe and Mail
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug - Yahoo Finance
Targeting the Immune System and Beyond: The Potential for Safe and Durable Responses in Higher-Risk Myelodysplastic Syndromes with Immuno-Myeloid Therapy - EMJ
ONTX stock dives 16%, DVAX stock in green after clinical data - Kalkine Media
What's going on in today's pre-market session - ChartMill
Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer - GlobeNewswire
Why Onconova Therapeutics (ONTX) Stock Is Up Sharply - Market Realist
Onconova Therapeutics (ONTX) Stock Live Price, Chart & News - CoinCodex
ONTX Stock: Why Biopharma Onconova Therapeutics Is Shooting Higher Today - InvestorPlace
PrimoHoagies is on a roll, adding 21 stores, while Penn-backed Carisma raises cash to fight cancer - Inquirer.com
Novel CDK4/6 Inhibitor ON 123300 Receives Green Light to Move Into Phase 1 Testing in Relapsed/Refractory Advanced Cancers - OncLive
Onconova Therapeutics Stock Price Forecast. Should You Buy ONTX? - StockInvest.us
Onconova Therapeutics Appoints James J. Marino, JD, MBA as Chairman of the Board of Directors - citybiz
Onconova On The Edge After Phase III Rigosertib MDS Failure - Citeline News & Insights
Are These On Your List Of Penny Stocks To Trade This Week? - PennyStocks.com
Penny Stocks To Watch Before Next Week; 1 Up Over 370% In June 2020 - PennyStocks.com
Onconova Therapeutics Inc Files For Mixed Shelf Of Up To $150 Million - Reuters
ONTX Stock Price, Quote & Chart | ONCONOVA THERAPEUTICS INC (NASDAQ:ONTX) - ChartMill
Bucks County biopharm firm names new CEO - The Business Journals
Onconova Therapeutics Announces New CEO Appointment - Global Banking & Finance Review
Hedge Fund and Insider Trading News: Michael Novogratz, Ray Dalio, Onconova Therapeutics Inc. (ONTX), Cerecor Inc (CERC), Spirit of Texas Bancshares Inc (STXB), L3 Technologies Inc (LLL), and More - Insider Monkey
Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib - Reuters
Onconova Therapeutics Announces Closing of $10 Million - GlobeNewswire
Onconova Therapeutics to Present at Biotech Showcase in January - GlobeNewswire
Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - marketexclusive.com
Onconova Therapeutics Announces Data on Improved - GlobeNewswire
Onconova Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Onconova Therapeutics Inc (ONTX): How Does It Impact Your Portfolio? - Yahoo Finance
Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting - GlobeNewswire
온코노바 세러퓨틱스 (ONTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):